Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.
Scientists at the University of Sussex could be a step closer to developing the first-ever blood test to diagnose the most aggressive type of brain cancer, glioblastoma.
Glioblastoma, a cancer that arises in the brain's supporting glial cells, is one of the worst diagnoses a child can receive. The grade IV, highly malignant tumor aggressively infiltrates healthy brain tissue, and most children die of the disease within one to two years of diagnosis, similar to adults.
A combination of chemotherapy drugs during brain cancer surgery using a biodegradable paste, leads to long-term survival, researchers at the University of Nottingham have discovered.
Using human cancer cells, tumor and blood samples from cancer patients, researchers at Johns Hopkins Medicine have uncovered the role of a neurotransmitter in the spread of aggressive cancers. Neurotransmitters are chemical "messengers" that transmit impulses from neurons to other target cells.
Scientists from Far Eastern Federal University in cooperation with colleagues from Blokhin Russian Cancer Research Center, Switzerland, and Sweden for the first time studied proteins, which constitute WNT signaling pathway of the cancer stem cells of glioblastoma multiforme (GBM CD133+ CSCs), one of the most aggressive brain tumors.
University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.
How does cancer spread? While studying human brain tumor cells, a team of scientists at the Research Institute of the McGill University Health Centre found some answers to this crucial, yet so far unanswered question.
Today, Penn Medicine is announcing the newest Translational Center of Excellence in the Abramson Cancer Center, focused on Glioblastoma Multiforme, the most common and lethal form of brain cancer.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.
Zika virus infection is a dreaded one that can lead to severe brain damage in the unborn babies of mothers who get it.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.
Scientists at Virginia Commonwealth University believe they have uncovered an "Achilles heel" of glioblastoma multiforme, the most common and deadly form of brain cancer.
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.
Precision cancer treatment relies on obtaining molecular information about the tumor to guide effective treatment decisions.
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.
A large European research collaboration is bringing new technology to bear to combat two of the most aggressive brain cancers.
Glioblastoma multiforme is the most common and aggressive primary brain tumor and has one of the worst survival rates of all cancers.
A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.
Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time.
Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute, an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California.